Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe

Executive Summary

AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.

Advertisement

Related Content

2013’s Most Notable Stories In “The Pink Sheet” DAILY
European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers
Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A
Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide
Germany’s HTA Process May Ease After Scientific Associations’ Input
Sunshine Act Payment Comparisons Likely Cloudy Due To Disclosure Judgment Calls
AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems
Walgreens Grows Internationally With Alliance Boots Stake
Ireland Cuts Drug Prices And May Also Introduce Reference Pricing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel